Cover Image
市場調查報告書

雷葛氏症候群:全球臨床實驗趨勢

Lennox-Gastaut Syndrome Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 235313
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
雷葛氏症候群:全球臨床實驗趨勢 Lennox-Gastaut Syndrome Global Clinical Trials Review, H2, 2017
出版日期: 2017年11月30日 內容資訊: 英文 80 Pages
簡介

本報告提供全球雷葛氏症候群治療藥的臨床試驗情形之調查,依各階段,各進展狀況闡明主要國家的雷葛氏症候群相關臨床實驗數量,主要企業·機關的簡介等。

簡介

  • 雷葛氏症候群
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量

G7各國臨床實驗數量:中樞神經系統 (CNS) 疾病臨床實驗的>雷葛氏症候群的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:中樞神經系統 (CNS) 疾病臨床實驗的雷葛氏症候群的比例

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標的達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

雷葛氏症候群治療藥臨床實驗的主要參與企業

有潛力的藥劑

最新臨床實驗新聞 雷葛氏症候群

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Eisai
    • H. Lundbeck A/S
    • GW Pharmaceuticals plc
    • INSYS Therapeutics, Inc.
    • SymPhar Sp. z.o.o.
    • ProductLife Group SA
    • Mylan Inc.
    • Johnson & Johnson
    • GlaxoSmithKline plc
    • Ajanta Pharma Limited
  • 有代表性的研究機關·醫院臨床實驗概要
    • Epilepsieklinik Tabor
    • L'Institution de Lavigny
    • University of Colombo
    • National Institute of Neurological Disorders and Stroke
    • National Center for Research Resources

5個有代表性的臨床實驗簡介

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4706CTIDB

GlobalData's clinical trial report, "Lennox-Gastaut Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Lennox-Gastaut Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Clinical Trials by G7 Countries: Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 14
  • Clinical Trials in G7 Countries by Trial Status 15
  • Clinical Trials by E7 Countries: Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials 16
  • Clinical Trials by Phase in E7 Countries 17
  • Clinical Trials in E7 Countries by Trial Status 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Lennox-Gastaut Syndrome Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Latest Clinical Trials News on Lennox-Gastaut Syndrome 28
  • Nov 24, 2017: Eisai To Present Data On Rufinamide At 71St American Epilepsy Society Annual Meeting 28
  • Oct 16, 2017: Zogenix Provides Update on ZX008 28
  • Clinical Trial Profile Snapshots 29

Appendix 78

  • Abbreviations 78
  • Definitions 78
  • Research Methodology 79
  • Secondary Research 79
  • About GlobalData 80
  • Contact Us 80
  • Source 80

List of Tables

List of Tables

  • Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 9
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 13
  • Lennox-Gastaut Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Lennox-Gastaut Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
  • Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 16
  • Lennox-Gastaut Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 17
  • Lennox-Gastaut Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Lennox-Gastaut Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 27
Back to Top